Eli Lilly & Co (LLY) Stock Price & Analysis
Eli Lilly & Co (LLY) fell 0.88% to USD 1,149.36 as of September 8, 2026 at 02:51 UTC, according to Nexqual real-time market data.
LLY last closed at USD 1,149.36; the session ranged USD 1,138.31–1,158.43 on volume of 2,159,931 shares. Market capitalization is —, with a 52-week range of USD 712.05–1,292.65 (NYQ). Source: Nexqual, September 8, 2026 at 02:51 UTC.
Key Statistics (as of September 8, 2026 at 02:51 UTC)
| Price | USD 1,149.36 |
|---|---|
| Change | ▼ 0.88% (down) |
| Previous Close | USD 1,149.36 |
| Open | USD 1,149.36 |
| Day Range | USD 1,138.31 – 1,158.43 |
| 52-Week Range | USD 712.05 – 1,292.65 |
| Volume | 2,159,931 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (LLY)
Nexqual's technical model rates LLY "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 02:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.83 (neutral) |
| vs SMA50 | Below (USD 1,191.5) |
| MACD | -7.65 (negative) |
From Eli Lilly & Co's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA), the FDA exercises jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products and devices.
- Currently, these government prices generally apply beginning at nine years (for medicines approved under a New Drug Application) or thirteen years (for medicines approved under a Biologics License Application) following FDA approval or licensure for the molecule and are set at a price that generally represents a significant discount from existing list prices to wholesalers and direct purchasers.
Partnerships
- In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices effective in 2026.
- To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRK | Merck & Company, Inc. | USD 150.33 | ▼ 0.86% |
| BMY | Bristol-Myers Squibb Company | USD 66.82 | ▼ 1.24% |
| NVO | Novo Nordisk A/S | USD 46.6 | ▼ 0.36% |
| ABT | Abbott Laboratories | USD 108.33 | ▼ 1.94% |
| AVGO | Broadcom Inc. | USD 357.9 | ▼ 2.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:51 UTC. This page is informational and not investment advice.